As of Oct 02
| +0.06 / +2.64%|
The 1 analysts offering 12-month price forecasts for Navidea Biopharmaceuticals Inc have a median target of 2.15, with a high estimate of 2.15 and a low estimate of 2.15. The median estimate represents a -7.73% decrease from the last price of 2.33.
The current consensus among 1 polled investment analysts is to Buy stock in Navidea Biopharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.